Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab SC vs IV in Relapsing Multiple Sclerosis
NCT07211633Phase 3Active, not recruiting
- Sponsor
- TG Therapeutics, Inc.
- Start
- Jul 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of ublituximab in multiple sclerosis (MS), sponsored by TG Therapeutics, Inc.. Started Jul 2025; status: active, not recruiting.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07211633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07211633.